COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    AFT 27
Previous Study | Return to List | Next Study

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03498716
Recruitment Status : Recruiting
First Posted : April 17, 2018
Last Update Posted : September 23, 2020
Breast International Group
Alliance Foundation Trials (AFT)
Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)
Frontier Science and Technology Research Foundation Inc (FS)
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 15, 2022
Estimated Study Completion Date : March 24, 2023